Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

April Egbert

Nurse Practitioner, Family Mount Orab, OH Nurse Practitioner

NPI 1780131052 CMS profile 10699285

111 Vandament Way, Mount Orab, OH 45154

Open in the dashboard

General payments

$78,493

732 records reported · program years 2021–2025

Research payments

$280

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, April Egbert of Mount Orab, OH is reported in the CMS Open Payments database as having received $78,493 across 732 general payments and $280 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,891 130
2024 General $20,811 166
2023 General $23,385 203
2022 General $15,445 165
2022 Research $280 1
2021 General $5,961 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • April Egbert
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to April Egbert were reported at $12,891. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year April Egbert Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $5,961 $124 $35–$379 $132
2022 $15,445 $141 $44–$430 $149
2023 $23,385 $154 $49–$476 $160
2024 $20,811 $165 $51–$504 $164
2025 $12,891 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $66,085 319 payments
  2. Abbott Laboratories $4,678 118 payments
  3. Boston Scientific Corporation $1,882 52 payments
  4. AbbVie, Inc. $1,122 72 payments
  5. Vertos Medical, Inc. $749 18 payments
  6. Collegium Pharmaceutical, Inc. $695 43 payments
  7. Nevro Corp. $376 5 payments
  8. Saluda Medical Americas, Inc. $304 9 payments
  9. Relievant Medsystems, Inc. $293 5 payments
  10. BIOTRONIK NRO, Inc. $244 5 payments
  11. Other $2,063 86 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $38,768 21 payments
  2. Travel and Lodging $20,804 115 payments
  3. Food and Beverage $18,046 591 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $875 5 payments
Products named General payments · program years 2021–2025
  1. SYNCHROMEDII $48,013 177 payments
  2. INTELLIS ADAPTIVESTIM $9,242 79 payments
  3. SYNCHROMED $3,332 3 payments
  4. VANTA ADAPTIVESTIM $3,302 15 payments
  5. PROCLAIM $2,769 93 payments
  6. INTELLIS $1,295 12 payments
  7. AXIUM $938 2 payments
  8. UBRELVY $876 58 payments
  9. QULIPTA $823 47 payments
  10. mild Device Kit $749 18 payments
  11. Other $8,055 285 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Medtronic, Inc. $280 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

6,087

Median for Nurse Practitioner: 389

Drug cost

$190,951

Median for Nurse Practitioner: $21,885

Branded share of claims

42.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,413 $42,117
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 931 $19,429
Oxycontin Oxycodone Hcl Brand 33 $13,778
Pregabalin Generic 299 $12,522
Gabapentin Generic 956 $12,482
Buprenorphine Generic 58 $11,654
Belbuca Buprenorphine Hcl Brand 21 $11,560
Linzess Linaclotide Brand 21 $11,144
Oxycodone Hcl Generic 345 $7,652
Movantik Naloxegol Oxalate Brand 13 $6,897

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$100,267

Medicare's payments for the services billed

Medicare patients

204

Average age 68

Services billed

1,498

113 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 46%
Depression 40%
COPD 36%
Ischemic heart disease 32%
Chronic kidney disease 24%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $194
$194 21 —
UBRELVY
  • AbbVie, Inc. $162
$162 — —
QULIPTA
  • AbbVie, Inc. $137
$137 — —
Prialt
  • TerSera Therapeutics LLC $49
$49 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $36
$36 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

733 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record